Monoclonal humanized monovalent antibody blocking therapy for anti-NMDA receptor encephalitisAtsuo Kanno(Astellas Pharma (Japan)), Mitsuyuki Matsumoto(Astellas Pharma (United States))Nature CommunicationsJune 17, 202510.1038/s41467-025-60628-1Cited by 8SaveCiteExport RISWatch citationsRelated PapersAdult Neurogenesis Transiently Generates Oxidative Stress|PLoS ONE|2012|119Gastrin-Releasing Peptide Contributes to the Regulation of Adult Hippocampal Neurogenesis and Neuronal Development|Stem Cells|2014|19Monoclonal humanized monovalent antibody blocking therapy for anti-NMDA receptor encephalitis|Unknown|2025|0